Atea Pharmaceuticals, Inc. director Bruce Polsky filed a Form 144 notice on November 17, 2026, disclosing a proposed sale of 8,720 shares of common stock acquired through a stock option exercise on the same date.
Key Highlights
- Proposed sale: Bruce Polsky, a director of Atea Pharmaceuticals, intends to sell 8,720 shares of common stock.
- Aggregate market value: The 8,720 shares carry an aggregate market value of $35,155.55, according to the filing.
- Acquisition method: The shares were acquired via a stock option exercise from the issuer on November 17, 2026, with payment made in cash.
- Broker: The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
- Prior sales: The filing discloses that Polsky sold 14,254 shares of common stock on November 16, 2026, with gross proceeds of $60,840.35.
- Shares outstanding: According to the filing, 80,304,145 shares of Atea Pharmaceuticals common stock were outstanding at the time of the notice.
- Exchange listing: The securities are listed on NASDAQ.
Atea Pharmaceuticals Director Polsky Files Rule 144 Notice for November 2026 Option-Derived Shares
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) director Bruce Polsky submitted a Form 144 notice dated November 17, 2026, disclosing his intent to sell 8,720 shares of the company's common stock on that same date. According to the filing, the shares were obtained through a stock option exercise from the issuer, with the acquisition date and the date of cash payment both recorded as November 17, 2026.
The filing reports an aggregate market value of $35,155.55 for the 8,720 shares proposed for sale. The notice identifies Morgan Stanley Smith Barney LLC Executive Financial Services as the broker through which the transaction is expected to occur. At the time of the notice, the filing states that 80,304,145 shares of Atea Pharmaceuticals common stock were outstanding.
As required under Rule 144, the filing also discloses Polsky's securities sales during the prior three months. The notice records a sale of 14,254 shares of common stock on November 16, 2026, with gross proceeds of $60,840.35. By signing the notice, Polsky represented, as stated in the form, that he "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed." Atea Pharmaceuticals is headquartered at 225 Franklin Street, Suite 2100, Boston, Massachusetts 02110.
What Was Disclosed
Bruce Polsky, a director at Atea Pharmaceuticals, filed a Rule 144 notice proposing the sale of 8,720 option-exercised shares valued at $35,155.55 on November 17, 2026, while also reporting a prior sale of 14,254 shares on November 16, 2026, for gross proceeds of $60,840.35.




Please wait processing your request...